Kobayashi Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Satoshi Yamane

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.01%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Satoshi Yamane (64 yo)

less than a year

Permanencia

Mr. Satoshi Yamane is President of Kobayashi Pharmaceutical Co. Ltd. from July 2024 and serves as Senior MD & Head of Sustainability Management Headquarters since January 2024. He was General Manager of Gr...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Satoshi Yamane	President	18.4yrs	sin datos	0.011% € 301.2k
Kunio Ito	Independent Outside Director	11.4yrs	sin datos	sin datos
Yoshiro Katae	Independent Outside Director	2.7yrs	sin datos	sin datos
Yoko Hatta	Outside Audit & Supervisory Board Member	9.4yrs	sin datos	sin datos
Kaori Sasaki	Independent Outside Director	8.4yrs	sin datos	sin datos
Ikeaki Ariizumi	Independent Outside Director	2.7yrs	sin datos	sin datos
Takashi Kawanishi	Full-time Audit & Supervisory Board Member	3.7yrs	sin datos	sin datos
Sumio Moriwaki	Outside Audit & Supervisory Board Member	1.7yrs	sin datos	sin datos

6.0yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de KOY se considera experimentada (6 años de antigüedad promedio).

Kobayashi Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Third quarter 2024 earnings released: EPS: JP¥52.57 (vs JP¥100 in 3Q 2023)

Kobayashi Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

New minor risk - Profit margin trend

Kobayashi Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of JP¥44.00 per share

First quarter 2024 earnings released: EPS: JP¥13.13 (vs JP¥47.43 in 1Q 2023)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

New minor risk - Share price stability

Now 20% overvalued

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: JP¥268 (vs JP¥260 in FY 2022)

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 09, 2024

Upcoming dividend of JP¥53.00 per share at 1.5% yield

New minor risk - Shareholder dilution

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,924,600 shares, representing 2.53% for ¥11,999.88 million.

Third quarter 2023 earnings released: EPS: JP¥100 (vs JP¥88.00 in 3Q 2022)

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) acquired Focus Consumer Healthcare, LLC.

Second quarter 2023 earnings released: EPS: JP¥55.91 (vs JP¥54.70 in 2Q 2022)

Upcoming dividend of JP¥39.00 per share at 1.1% yield

First quarter 2023 earnings released: EPS: JP¥47.43 (vs JP¥44.86 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥260 (vs JP¥252 in FY 2021)

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Upcoming dividend of JP¥47.00 per share

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on May 10, 2023

Third quarter 2022 earnings released: EPS: JP¥88.00 (vs JP¥89.58 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥87.99 (vs JP¥89.58 in 3Q 2021)

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.

Second quarter 2022 earnings released: EPS: JP¥54.70 (vs JP¥54.41 in 2Q 2021)

Upcoming dividend of JP¥38.00 per share

First quarter 2022 earnings released: EPS: JP¥44.86 (vs JP¥46.42 in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Upcoming dividend of JP¥44.00 per share

Third quarter 2021 earnings released: EPS JP¥89.58 (vs JP¥90.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥54.41 (vs JP¥57.27 in 2Q 2020)

Upcoming dividend of JP¥35.00 per share

First quarter 2021 earnings released: EPS JP¥46.42 (vs JP¥47.87 in 1Q 2020)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2021 Results on Apr 27, 2021

New 90-day low: €83.50

New 90-day low: €85.00

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Revenue misses expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 01, 2021

New 90-day high: €104

Upcoming Dividend of JP¥41.00 Per Share

New 90-day high: €99.50

New 90-day high: €92.00

Revenue misses expectations

Third quarter 2020 earnings released: EPS JP¥90.07

New 90-day high: €83.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

New 90-day high: €83.00

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.

New 90-day high: €81.00

First half earnings released

New 90-day low - €73.00

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad